Results 261 to 270 of about 2,634,864 (332)

GlycoRNA, a novel RNA modification. [PDF]

Discov Oncol
Hu B, Ma T, Zhou D, Jiao J, Xia X.
europepmc   +1 more source

CSF Mitochondrial DNA: Biomarker of Body Composition and Energy Metabolism in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cerebrospinal fluid (CSF) cell‐free mitochondrial DNA (cf‐mtDNA) is a potential biomarker for Parkinson's disease (PD), but its clinical relevance remains unclear. We investigated associations between CSF cf‐mtDNA levels, body composition, nutritional status, and metabolic biomarkers in PD. Methods CSF cf‐mtDNA levels, defined as the
Yasuaki Mizutani, Tsuyoshi Nakai, Yasuhiro Maeda, Reiko Ohdake, Atsuhiro Higashi, Toshiki Maeda, Ryunosuke Nagao, Sayuri Shima, Kazuya Kawabata, Akihiro Ueda, Mizuki Ito, Hirohisa Watanabe   +11 more
wiley   +1 more source

NET degradation attenuates ricin-induced acute lung injury and protects mice from ARDS. [PDF]

Mol Med
Sapoznikov A, Evgy Y, Fux L, Ruderfer I, Nataf Y, Hayon Y, Zamin S, Mizrachi R, Pessah R, Gal Y, Ben-David A, Erez N, Falach R.   +12 more
europepmc   +1 more source

Exosome Proteomics of SOD1D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease. Super oxide dismutase 1 (SOD1) gene mutations cause ALS, and the D90A mutation is associated with primarily upper motor neuron (UMN) loss. Objective Our goal is to reveal the early cellular events in ALS pathology and identify potential pharmacokinetic biomarkers, using well ...
Mukesh Gautam, Ali Laith, Aslihan Gunel, Melda Yilmaz, Nazli Basak, Halil Idrisoglu, P. Hande Ozdinler   +6 more
wiley   +1 more source

Deciphering the dialogue between the bovine blastocyst and the uterus: embryo-induced alterations in extracellular vesicle protein content from an ex vivo model and the in vivo environment. [PDF]

J Anim Sci Biotechnol
Mazzarella R, Sánchez JM, Egido SG, McDonald M, Álvarez-Barrientos A, González E, Falcón-Pérez JM, Azkargorta M, Elortza F, González ME, Lonergan P, Rizos D, Fernandez-Fuertes B.   +12 more
europepmc   +1 more source

FORMATION OF EXTRACELLULAR SPHINGOLIPIDES BY MICROORGANISMS

, 1960
Lynferd J. Wickerham, Frank H. Stodola
openalex   +1 more source

SNUPN‐Related Muscular Dystrophy: Novel Phenotypic, Pathological and Functional Protein Insights

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SNUPN‐related muscular dystrophy or LGMDR29 is a new entity that covers from a congenital or childhood onset pure muscular dystrophy to more complex phenotypes combining neurodevelopmental features, cataracts, or spinocerebellar ataxia. So far, 12 different variants have been described.
Nuria Muelas, Pablo Iruzubieta, Alberto Damborenea, Laura Pérez‐Fernández, Inmaculada Azorín, Juan Carlos Jiménez García, Ana Töpf, Pilar Martí, Lorena Fores‐Toribio, María Manterola, Rosana Blanco‐Mañez, Oihane Pikatza‐Menoio, Sonia Alonso‐Martín, Volker Straub, Aitziber L. Cortajarena, Adolfo López de Munain, David De Sancho, Lorea Blázquez, Juan J. Vilchez   +18 more
wiley   +1 more source

Intracellular amyloidosis in peripheral nerve and skeletal muscle. [PDF]

J Neuropathol Exp Neurol
Grafham GK, Mak G, Grant S, Murphy A, Baker SK, Tarnopolsky M, Lu JQ.   +6 more
europepmc   +1 more source

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu, Oliver Robinson, Christina M. Lill, Anna Matton, Raquel Puerta, Pilar Sanz, Merce Boada, Agustín Ruiz, Lefkos Middleton, for the Alzheimer's Disease Neuroimaging Initiative   +9 more
wiley   +1 more source

Multicenter randomized trial assessing efficacy and safety of aerosolized dornase Alfa in COVID-19 ARDS. [PDF]

Sci Rep
Gregoire C, Di Meglio L, Le Cossec C, Ho-Tin-Noé B, Nomenjanahary MS, Guillaume J, Hamdani M, Losser MR, Lambiotte F, Le Tacon S, Cantier M, Engrand N, Yavchitz A, Trouiller P, Desilles JP, Pottecher J.   +15 more
europepmc   +1 more source